BridgeBio Oncology Therapeutics, Inc. (BBOT) — Net Asset Momentum
BridgeBio Oncology Therapeutics, Inc. (BBOT) recorded a net asset momentum of 117.8% as of December 2025, with net assets of $411.10 Million USD. Net Asset Momentum measures the year-over-year percentage change in net assets (total assets minus total liabilities), indicating how rapidly the company is building or eroding its equity base. See BBOT total equity for net asset value and shareholders' equity analysis.
YoY Momentum
Current Net Assets
Years of Data
Country
BridgeBio Oncology Therapeutics, Inc. Net Asset Momentum (2021–2025)
This chart tracks BridgeBio Oncology Therapeutics, Inc.'s year-over-year net asset growth across 5 annual reporting periods from 2021 to 2025. The most recent momentum reading is +117.8%, with net assets of $411.10 Million USD as of December 2025. For live market cap and overall valuation, see market value of BridgeBio Oncology Therapeutics, Inc..
Annual Net Asset History for BridgeBio Oncology Therapeutics, Inc. (2021–2025)
The table below shows the complete annual net asset history for BridgeBio Oncology Therapeutics, Inc. from 2021 to 2025, covering 5 yearly periods. Each row includes total assets, total liabilities, net assets, and the year-over-year momentum figure for that period. Check BridgeBio Oncology Therapeutics, Inc. (BBOT) tangible equity ratio to evaluate the tangible quality of the company's equity base.
| Year | Net Assets (USD) | Total Assets | Total Liabilities | YoY Momentum |
|---|---|---|---|---|
| 2025 | $411.10 Million | $448.38 Million | $37.28 Million | ▲ +117.8% |
| 2024 | $188.72 Million | $194.42 Million | $5.71 Million | ▲ +296969.0% |
| 2023 | $-63.57K | $332.89K | $396.46K | ▼ -190.6% |
| 2022 | $-21.88K | $144.58K | $166.46K | ▼ -19.2% |
| 2021 | $-18.36K | $144.28K | $162.64K | — |